Using positron emission tomography (PET) researchers associated with the journal ‘Biological Psychiatry’ have found out that a mechanism of brain inflammation is a major reason behind the development of schizophrenia. This has led them to suggest that anti-inflammatory agents hold a potential for use in the treatment of schizophrenia. They further maintain that medications under this category with powers to target, especially, the activation of microglia need to be studied.